Journal: bioRxiv

Article Title: Neutralization and Stability of SARS-CoV-2 Omicron Variant

doi: 10.1101/2021.12.16.472934

Figure Lengend Snippet: ( a ) Diagrams of SARS-CoV-2 S variants used for pseudotyping, which indicate the location of specific mutations as well as the S1 and S2 subunits of S, the N-Terminal Domain (NTD), Receptor Binding Domain (RBD), Fusion Peptide (FP), and Trans-membrane domain (TM). ( b ) Infectivity of pseudotyped viruses produced in parallel for infection of HEK293T cells stably expressing ACE2. ( c ) Infectivity of pseudotyped lentivirus in human lung epithelia-derived CaLu-3 cell line. Bars in b and c represent means +/- standard deviation, and significance is determined by one-way ANOVA with Bonferroni’s multiple testing correction. Results of at least 3 independent experiments are averaged and shown. ( d ) Sera from 48 HCWs collected 3-4 weeks after second mRNA vaccine dose was used to neutralize pseudotyped virus for variants, and the resulting 50% neutralization titers (NT 50 ) are displayed. ( e ) Sera from 23 HCWs following homologous mRNA booster vaccination were assessed for nAb titers. ( f ) Sera from 9 ICU COVID-19 patient samples and 9 hospitalized non-ICU COVID-19 patient samples collected in 2020 prior to the approval of any SARS-CoV-2 vaccines were assessed for nAb titers. ( g ) Sera from 19 ICU COVID-19 patient samples collected during the Delta-wave of the pandemic were assessed for nAb titers. Mean NT 50 values in panels d-g are displayed at the top of plots along with relative neutralization sensitivity with D614G set to 100%; bars represent mean +/- standard error, and significance relative to D614G is determined by one-way ANOVA with Bonferroni’s multiple testing correction. ( h ) Heat maps showing patient/vaccinee NT 50 values against each variant. Patient/vaccinee numbers are identified as P for Pfizer/BioNTech BNT162b2 vaccinated/boosted HCW, M for Moderna mRNA-1273 vaccinated/boosted HCW, I for ICU patient samples collected during the 2020 D614G-wave, H for hospitalized non-ICU patient samples collected during the 2020 D614G-wave, or D for ICU patient samples collected during the Delta-wave. P-values are represented as *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant.

Article Snippet: Sera were collected 3-5 weeks post second vaccine dose for 48 HCWs which included 20 Moderna mRNA-1273 and 28 Pfizer/BioNTech BNT162b2 vaccinated HCWs.

Techniques: Binding Assay, Infection, Produced, Stable Transfection, Expressing, Derivative Assay, Standard Deviation, Neutralization, Variant Assay

Journal: Transplant Infectious Disease

Article Title: Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

doi: 10.1111/tid.13813

Figure Lengend Snippet: Deficient CoV‐2 T cells in vaccinated renal transplant patients. Fresh whole blood was stimulated with SARS‐CoV‐2 Spike peptides overnight. CoV‐2‐specific CD4+ (A) and CD8+ (B) were enumerated in healthy controls and transplant recipients (Tx) ≥1 month post‐second dose of BNT162b2 vaccine. The dotted line represents the cutoff level (0.05%) for positive CoV‐2 T cells. * p < .05, *** p < .001

Article Snippet: Kidney transplant recipients who were greater than 1 month post‐second dose of the Pfizer BNT162b2 mRNA vaccine had determinations of Spike‐receptor binding domain (RBD)‐specific IgG levels and analysis of Spike‐specific CD4+/CD8+ T‐cell immune responses.

Techniques:

Journal: Transplant Infectious Disease

Article Title: Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

doi: 10.1111/tid.13813

Figure Lengend Snippet: Effect of immunosuppression on T‐cell responses in vaccinated transplant recipients. (A) Transplant recipients were divided into two groups based on immunosuppression: belatacept + mycophenolate + prednisone (Bela) versus tacrolimus + mycophenolate + prednisone (Tac). CoV‐2 Spike‐specific CD4+ and CD8+ T cells were compared 1 month post‐second dose of BNT162b2 vaccine. (B) Similar to (A), cytomegalovirus‐specific cytotoxic T cells (CMV‐Tc) responses were compared between Bela and Tac treated transplant recipients. (C) The percentages of Bela and Tac recipients with CMV‐Tc (CMV) and/or SARS‐CoV‐2‐specific T‐cell responses (CoV‐2T) (CoV2) were analyzed. NS: not significant ( p > .05), * p < .05

Article Snippet: Kidney transplant recipients who were greater than 1 month post‐second dose of the Pfizer BNT162b2 mRNA vaccine had determinations of Spike‐receptor binding domain (RBD)‐specific IgG levels and analysis of Spike‐specific CD4+/CD8+ T‐cell immune responses.

Techniques:

Journal: Transplant Infectious Disease

Article Title: Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

doi: 10.1111/tid.13813

Figure Lengend Snippet: Immunoglobin G (IgG) serology in vaccinated renal transplant recipients. (A/B) Plasma was collected from healthy individuals (Controls), belatacept recipients (Bela), and Tacrolimus recipients (Tac) 1 month post‐second dose of BNT162b2 vaccine. The CoV‐2 Spike (S) receptor binding domain (RBD)‐specific IgG levels in plasma were measured by ELISA. Each dot represents one individual (A) and percentages of recipients with positive IgG serology and/or CoV‐2 T cells (either CD4+ or CD8+) were analyzed in (B). Dotted line represents the cutoff level of 15 unit/ml for a positive IgG serology. NS: not significant ( p > .05), *** p < .001

Article Snippet: Kidney transplant recipients who were greater than 1 month post‐second dose of the Pfizer BNT162b2 mRNA vaccine had determinations of Spike‐receptor binding domain (RBD)‐specific IgG levels and analysis of Spike‐specific CD4+/CD8+ T‐cell immune responses.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay

Journal: Transplant Infectious Disease

Article Title: Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

doi: 10.1111/tid.13813

Figure Lengend Snippet: Humoral and cellular vaccine responses to BNT162b2 in transplant patients (Tx) and healthy controls (HC)

Article Snippet: Kidney transplant recipients who were greater than 1 month post‐second dose of the Pfizer BNT162b2 mRNA vaccine had determinations of Spike‐receptor binding domain (RBD)‐specific IgG levels and analysis of Spike‐specific CD4+/CD8+ T‐cell immune responses.

Techniques:

Journal: PLOS ONE

Article Title: Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 m RNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

doi: 10.1371/journal.pone.0281673

Figure Lengend Snippet: In 30 random participants anti-RBD IgG specific B memory cells were measured using commercially available ELISPOT kit (Mabtech). Data are plotted for participants with dosing interval = <42 days (<35-days and 35-42-days groups combined) and >42-days group with the adjusted mean provided for each group. Comparison was performed using linear mixed effects model adjusted for age, sex, education, smoking, alcohol use, body-mass index, known comorbidities (cardiovascular, neoplastic, autoimmune, renal and chronic respiratory diseases) and the number of days after 2 nd vaccine dose to subsequent blood draw.

Article Snippet: SARS-CoV-2 RBD specific memory B cells were quantified from PBMC collected at 3 months post-second dose, using a commercially available ELISPOT kit (Mabtech).

Techniques: Enzyme-linked Immunospot, Comparison